
United Kingdom · Medical devices startup
Ceryx Medical Ltd is a Medtech company based in Cardiff, Wales, founded in 2016 as a spin-out from the Universities of Bath and Bristol.
Funding reportedLast round: Seed
Ceryx Medical Ltd is a Medtech company based in Cardiff, Wales, founded in 2016 as a spin-out from the Universities of Bath and Bristol.
The company focuses on developing bioelectronic medical devices, particularly aimed at treating heart failure. Ceryx Medical is known for its proprietary microchip technology that mimics the body's natural nerve centers, known as Central Pattern Generators (CPGs), to restore normal autonomic functions disrupted by disease or injury. The company's lead product, Cysoni, is a cardiac rhythm management device designed to improve heart function and patient quality of life by synchronizing cardiac and respiratory rhythms. Ceryx Medical is also developing Cysoni-XT, a temporary cardiac pacemaker for post-surgical recovery. With a small team and significant early-stage funding, Ceryx Medical is advancing its products toward clinical evaluations, aiming to provide innovative therapies for heart failure and other autonomic disorders.
Funding, as reported
Ceryx Medical Ltd filed 2 raises, $12M in all. Filings say how much was sold and to how many investors; they never name the investors.
From Ceryx Medical Ltd's own website: 1 founder, 4 on the team.
What they build
Known for
health careartificial neuronsmedical implantsbioelectronic devicesmedical equipment manufacturingbiomimetic designcardiac performance restorationhospital & health careblood pressure modulationspinal cord injury restorationhealthanalogue circuitrycentral pattern generatorsservicesmedical devicesreal-time physiological signals
Built with from their website
Google Cloud CDNWordPress.orgGoogle CloudViewport MetaWordpress.comYoastHTTP/3VarnishwebpackWix
WordpressSentryMicrosoft Exchange OnlineGoogle Cloud HostingPriority HintsReactGoogle Font APIHSTS
Add your raise, your deck and your story, and put Ceryx Medical Ltd in front of investors. Or tell us what we have wrong.